Skip to main content
Erschienen in: Virchows Archiv 1/2024

Open Access 27.11.2023 | Original Article

Pathologic approach to Neonatal cholestasis with a simple scoring system for biliary atresia

verfasst von: Khadiga M. Ali, Khaled R. Zalata, Tarik Barakat, Sherine M. Elzeiny

Erschienen in: Virchows Archiv | Ausgabe 1/2024

Abstract

A liver biopsy is essential for the diagnostic workup of persistent neonatal cholestasis (NC). The differential diagnosis of NC is broad, including obstructive and non-obstructive causes. In addition, histologic features of certain disorders may be non-specific in the early course of the disease. To evaluate liver biopsies using a practical histopathologic approach for NC and to define a simple scoring system for biliary atresia (BA) for routine clinical practice. From June 2006 to December 2021, liver biopsy specimens from infants with persistent NC were examined by two independent pathologists. The cases diagnosed as BA were correlated with clinical, radiologic, and laboratory data to calculate the final score. Four hundred and fifty-nine cases were enrolled in the study. They had a mean age of 63.94 ± 20.62 days and were followed for a median time of 58 (1–191) months. They included 162 (35.3%) cases of BA. On multivariate analysis, portal edema, ductular proliferation, cholangiolitis, and bile duct/ductular plugs were the histopathologic predictors of BA. A liver biopsy did perform well with a 95.1% sensitivity, 91.6% specificity, 86% PPV, and 97.1% NPV. At a cutoff of 5 of the scoring system, diagnosis of BA could be done with a sensitivity of 95.1% and a specificity of 100%. We have shown detailed histopathologic features of BA with more depth to infants aged ≤ 6 weeks. We have developed a simple scoring system using a combination of liver biopsy with non-invasive methods to increase the diagnostic accuracy of BA.
Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1007/​s00428-023-03704-5.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
BA
Biliary atresia
DPM
ductal plate malformation
EMH
Extramedullary hematopoiesis
NC
Neonatal cholestasis
PFIC
Progressive familial intrahepatic cholestasis

Introduction

Neonatal cholestasis (NC) is described as an early-life defect in bile production or flow that causes the liver to retain biliary substances. Neonatal cholestasis affects about 1 in every 2500 live births [10]. Biliary atresia (BA), which has been reported to occur in 35–41% of cases, is the most common condition to be the primary cause of NC, followed by metabolic disorders (9–17%), progressive familial intrahepatic cholestasis (PFIC) (10%), Alagille syndrome (2–6%), infectious diseases (1–9%), and other causes, including idiopathic cases (13–30%) [12].
It is critical to quickly identify the underlying cause in order to start the right surgical or medicinal treatment. Early surgical referral is necessary in BA to increase success rates. In the case of treatable metabolic diseases, a prompt diagnosis justifies prompt, targeted therapy and a better prognosis [19].
Infants with cholestatic jaundice require a liver biopsy as part of their diagnostic work-up. Interpretation of the biopsies in this clinical setting is challenging. The differential diagnosis of NC is broad, including obstructive and non-obstructive causes. In addition, histologic features of certain disorders may change over time or may be non-specific in the early course of the disease [23].
In this study, we provided a practical histopathologic assessment of liver biopsies performed in infants presented with persistent NC. Based on the data of patients with confirmed diagnoses, we suggested a simple diagnostic scoring system for BA for everyday clinical practice.

Materials and methods

Patient selection

A retrospective study was conducted from June 2006 to December 2021 to review the medical charts of patients referred to a tertiary care center at the pediatric gastroenterology and hepatology unit at Mansoura University Children’s Hospital (MUCH), Egypt, who underwent a liver biopsy as a part of the diagnostic workup for persistent NC. Infants aged less than 120 days old were enrolled in the study. Premature infants were excluded. Informed consent from the participant’s parents or guardians was obtained. Approval for this study was obtained from the Mansoura Faculty of Medicine institutional review board (R.21.11.1527).

Histopathologic evaluation of liver biopsies

Formalin-fixed, paraffin-embedded blocks of liver biopsy samples were retrieved from the pathology archive of the pathology laboratory at MUCH. The initial evaluation was performed using hematoxylin–eosin (H&E), Masson trichrome, Periodic Acid Schiff (PAS) before and after diastase, and Prussian blue stains. Immunohistochemical (IHC) staining for CK7 was done before a diagnosis of the paucity of bile ducts was made and to highlight ductal proliferation characterized by having a patent lumen compared to ductular proliferation that appears as strings of cuboidal cells in a ductular configuration located outside the limiting plate in questionable cases.
All biopsy specimens contained at least 10 portal tracts [8]. The paucity of bile ducts was defined as a bile duct to portal tract ratio of less than 0.5 (normal 0.9–1.8) after performing several serial sections with an IHC-stained slide for CK7 [17].
Histopathologic evaluation of all liver biopsies was performed by two pathologists experienced in pediatric liver diseases who were given only the age of patients but were blinded to the clinical data or final diagnosis. They set together and agreed on the histopathologic features assessed. Fourteen histopathologic items were assessed (Fig. 1, Table 1). Cytoplasmic cholestasis was graded into mild (some but not all hepatocytes are stained with bile pigment), moderate (diffuse bile-stained hepatocytes sparing Kupffer cells), and marked (diffuse bile-stained hepatocytes and Kupffer cells). Bile ductular proliferation was defined as increased bile ductules at the interface and graded as absent, mild (involving less than half the circumference of the portal tract), either focal (involving < 50% of the portal tract) or diffuse (> 50% of portal tracts) pattern, moderate or marked when the proliferation exceeds half the circumference of the portal tract either in some or most portal tracts respectively [20] (Fig. 1).
Table 1
Demographic, clinical, and laboratory and histopathologic features of 459 infants with neonatal cholestasis
Features
N (%)
Features
N (%)
Age groups
Sex
 28–60 Days
200 (43.6%)
 Boys
276 (60.1%)
 61–90 Days
213 (46.4%)
 Girls
183 (39.9%)
 91–120 Days
46 (10%)
  
Clay stool
 
Hepatomegaly
 
 Present
162 (35.3%)
 Present
202 (44%)
Diarrhea/failure to thrive
Congenital anomalies
 
 Present
19 (4.1%)
 Present
71 (15.5%)
TORCH screeninga
  
 Positive
64 (13.9%)
GGTb (IU/L) in different age groups
Radiology
 
median (IQRc)
 Suggestive of BA
134 (70.1%)
 28–60 days
281 (89–509)
 Not BA
322 (29.2%)
 61–90 days
302 (97.5–597)
 Non conclusive
3 (0.7%)
 91–120 days
164 (41.5–630.25)
  
Histopathologic features
1. Portal fibrosis
2. Bile ductular proliferation
 Absent
95 (20.7%)
 No
161 (35.1%)
 Mild fibrosis
170 (37%)
 Mild focal
76 (16.6%)
 Moderate fibrosis
117 (25.5%)
 Mild diffuse
77 (16.8%)
 Advanced fibrosis
76 (16.6%)
 Moderate or marked
145 (31.5%)
 Cirrhosis
1 (0.2%)
 
3. Portal tract edema
4. Ductal plate malformation
 Present
119 (25.9%)
 Present
47 (10.2%)
5. Cholangiolitis
6. Bile duct/ductular plugs
 Present
102 (22.2%)
 Present
250 (54.5%)
7. Portal inflammation
8. Parenchymal inflammation
 
 No
3 (0.7%)
No
241 (52.5%)
 Mild
353 (76.9%)
Mild
192 (41.8%)
 Moderate or marked
103 (22.4%)
Moderate or Marked
26 (5.7%)
9. Paucity of intrahepatic bile ducts
10. Secondary siderosis
Present
78 (17%)
Present
136 (29.6%)
11. Extramedullary hematopoiesis
12. Giant-cell transformation
Present
196 (42.7%)
Present
182 (39.7%)
13. Cholestasis
14. Steatosis
Mild
120 (26.1%)
Absent
419 (91.3%)
Moderate
335 (73%)
Mild<33%
7 (1.5%)
Marked
4 (0.9%)
Moderate 33%-66%
24 (5.2%)
Marked >66%
9 (2%)
Follow up result
Cause of death (96 cases)
 Living/dead
363 (79.1%)/ 96 (20.9%)
 Pneumonia
7 (7.3%)
 Sepsis
13 (13.5%)
 Hepatic encephalopathy
76 (79.2%)
Diagnosis pathologically
N (%)
Final clinical diagnosis
N (%)
 BAd
179 (39%)
 BA
162 (35.3%)
 Paucity
78 (17%)
 Paucity and alagille
83 (18.1%)
 NHe
143 (31.2%)
 NH
116 (25.3%)
 Cholestasis with steatosis
40 (8.7%)
 PFIC 36
12 (2.6%)
 Intrahepatic cholestasis
19 (4.1%)
 Congenital CMV infection
2 (0.4%)
 
 Choledocal cyst
4 (0.8%)
 PFIC-1 and PFIC-2f
18 (3.9%)
 Metabolic
54 (11.8%)
 Free
5 (1.1%)
 Others
3 (0.7%)
aTORCH toxoplasmosis, rubella cytomegalovirus, and herpes simplex, bGGT gamma-glutamyl-transferase, cIQR inter-quartile ratio, dBA biliary atresia, eNH neonatal hepatitis, fPFIC progressive familial intrahepatic cholestasis
Steatosis was graded into 4 grades, absent (< 5%), mild (5–33%), moderate (34–66%), or marked (≥ 67%) [15]. Other features are assessed either present or absent as giant cell transformation of hepatocytes, extramedullary hematopoiesis (EMH), portal edema which is characterized by portal tract expansion with clearing, ductal plate malformation (DPM) where the bile ducts are arranged around the central fibrovascular core and bile duct/ductular plugs. Fibrosis was assessed as absent, mild fibrosis (expansion of portal tracts without bridging), moderate fibrosis (presence of occasional bridging fibrosis), advanced fibrosis (presence of marked bridging fibrosis with occasional nodules), and finally development of cirrhosis.
When features of obstructive cholestasis were present as portal edema, expansion by fibrosis, bile ductular proliferation, and bile duct/ductular plugs with or without cholangiolitis), a suggestion of BA was made. The presence of hepatocyte disarray with giant cell transformation, EMH, and cholestasis with intact interlobular bile ducts was considered a neonatal hepatitis pattern of injury [6]. Pure intrahepatic cholestasis is characterized by the presence of bile inside the hepatocytes and/or bile canaliculi without significant portal or parenchymal alterations [17]. When steatosis is easily identified in addition to cholestasis, screening for metabolic disorders such as galactosemia, tyrosinemia, or hereditary fructose intolerance is suggested in the differential diagnosis [7]. When there is discordance between the two pathologists, they evaluate the discordant cases together to reach a final classification.

Data collection

Age at liver biopsy, sex, laboratory findings (total and direct bilirubin, gamma-glutamyl-transferase (GGT), and TORCH (toxoplasmosis, rubella cytomegalovirus (CMV), and herpes simplex) serological test results were gathered. Additional tests, such as the assessment of alpha-1 antitrypsin levels, the study of metabolic inborn errors, and the analysis of the polymerase chain reaction for CMV in the blood were collected.
Radiologic evaluations of the biliary tree, any concurrent congenital anomalies, and the date of Kasai surgery, if performed, were collected from the electronic registry system. Clinical follow-up information was obtained. A scoring system formed of 4 main parameters with a total score of 7 was applied to all cases in an attempt to differentiate between BA and non-BA cases.

Statistical analysis

For continuous variables, descriptive data were summarized as the mean ± standard deviation (SD) or median and quartiles, and for categorical variables, as numbers and percentages. Pearson correlation coefficients were calculated for pairs of histologic features to characterize their associations. To evaluate the association between histologic characteristics and BA, univariate and multivariate logistic regression were performed. Sensitivity, specificity, and positive and negative predictive (PPV, NPV) values were calculated with histologic assignment as the test condition, and the clinical diagnosis (BA or non-BA) was considered as the genuine illness state of each patient. The receiver operating characteristic (ROC) curve’s area under the curve (AUC) was used to evaluate the diagnostic performance of each variable and score. Statistical analysis was performed by using the Statistical Package for Social Science (SPSS) version 22 (Armonk, NY: IBM Corp).

Results

Four hundred and fifty-nine children were enrolled in the study. They included 276 boys and 183 girls. They had a mean age of 63.94 ± 20.62 days and were followed for a median time of 58 (1–191) months. Table 1 demonstrates the clinical, laboratory, and histologic features of all cases.

Clinically confirmed BA versus non-BA cases

We documented 162 (35.3%) cases of BA out of all 459 enrolled cases (Table 2). It was noted that with increasing patient age, the GGT level increased in the BA group (from 474 to 754 IU/L) compared to the decrease in the non-BA group (from 121 to 67 IU/L).
Table 2
Demographic, clinical, laboratory, and histopathologic features of BA and non-BA groups
 
Non-BAa group
N = 297
BAa group
N = 162
P-value*
Age groups
 28–60 Days
132 (44.4%)
68 (42%)
P = .74
 61–90 Days
134 (45.1%)
79 (48.8%)
 91–120 Days
31 (10.4%)
15 (9.3%)
Sex
 Male
187 (63%)
89 (54.9%)
P = .09
 Female
110 (37%)
73 (45.1%)
Clay stool: Present
0
162 (100%)
P < .001
Diarrhea/failure to thrive: Present
19 (6.4%)
0
P < .001
Hepatomegally: Present
90 (30.3%)
112 (69.1%)
P < .001
Congenital anomalies: Present
62 (20.9%)
9 (5.6%)
P < .001
GGTb (IU/L) in different age groups
Median (IQRc)
 
 28–60 Days
121 (57-359.75)
474 (360.5-613.25)
P < .001
 61–90 Days
124.5 (62-281.75)
567 (370-781)
P < .001
 91–120 Days
67 (35-169)
754 (430-891)
P < .001
TORCHd screening: Present
36 (12.1%)
28 (17.3%)
P = .13
Radiology
 Intact
296 (99.7%)
26 (16%)
P < .001
 Suggestive of BA
0
134 (82.7%)
 Non-conclusive
1 (0.3%)
2 (1.2%)
Histopathologic features
1. Portal fibrosis
   
  Absent
94 (31.6%)
1 (0.6%)
P < .001
  Mild fibrosis
138 (46.5%)
32 (19.8%)
  Moderate fibrosis
43 (14.5%)
74 (45.7%)
  Advanced fibrosis
22 (7.4%)
54 (33.4%)
  Cirrhosis
0
1 (0.6%)
2. Portal tract edema: Present
3 (1.0%)
116 (71.6%)
P < .001
3. Bile ductular proliferation
   
  No
159 (53.5%)
2 (1.2%)
P < .001
  Mild focal
71 (23.9%)
5 (3.1%)
  Mild diffuse
33 (11.1%)
44 (27.2%)
  Moderate or marked
33 (11.4%)
111 (68.5%)
4. Ductal plate malformation
P < .001
  Present
8 (2.7%)
39 (24.1%)
5. Bile duct/ductular plugs
91 (30.6%)
159 (98.1%)
P < .001
  Present
6. Portal inflammation
P = .01
  No
3 (1.0)
0
  Mild
215 (73.1%)
138 (85.2%)
  Moderate or Marked
79 (26.9%)
24 (14.8%)
7. Cholangiolitis: Present
35(11.8%)
67(41.4%)
P < .001
8. Paucity of intrahepatic bile ducts
  
P < .001
  Present
77 (25.9%)
1 (0.6%)
9. Secondary siderosis
P = .09
  Present
80 (26.9%)
56 (34.6%)
10. Cholestasis
  
P < .001
  Mild
104 (35%)
16 (9.9%)
  Moderate
192 (64.6%)
143 (88.3%)
  Marked
1 (0.3%)
3 (1.9%)
11. Parenchymal inflammation
P < .001
  No
116 (39.1%)
125 (77.2%)
  Mild,
156 (52.5%)
36 (22.2%)
  Moderate or marked
25 (8.4%)
1 (0.6%)
12. EMHe
P < .001
  Present
154 (51.9%)
42 (25.9%)
13. Giant-cell transformation
P < .001
  Present
144 (48.5%)
38 (23.5%)
14. Steatosis
P < .001
  Absent
257 (86.5%)
162(100%)
  Present
40 (13.5%)
0
Follow up result
 Dead
45 (15.2%)
51 (31.5%)
P < .001
 Living
252 (84.8%)
111 (68.5%)
Cause of death (96 cases)
 Hepatic encephalopathy
29 (64.4%)
47 (92.2%)
P = .003
 Pneumonia
5 (11.1%)
2 (3.9%)
 Sepsis
11 (24.4%)
2 (3.9%)
Follow up (in months)
75 (22-120)
38 (6–75.25)
P < .001
 Median (IQR3)
aBA, biliary atresia; bGGT, gamma-glutamyl-transferase; cIQR, inter-quartile ratio); dTORCH, toxoplasmosis, rubella cytomegalovirus, and herpes simplex); eEMH, extramedullary hematopoiesis
*P < .05 is significant 
At the histopathologic level, most of the BA cases showed bridging fibrosis (79.1 %) and moderate to marked bile ductular proliferation (68.5%) (P < .001). However, bile ductular proliferation was present to a variable degree in 46.5% of non-BA cases.
One hundred fifty-four cases out of 162 BA cases (95.1%) were clearly suggested on histopathologic examination, while the remaining 8 cases were missed as other diagnoses (7 cases with neonatal hepatitis pattern and one as paucity of intrahepatic bile duct). The mean age of the missing 8 cases was 29.75 (28–32) days. They were all presented with a clay stool with a median GGT level of 443 IU/L (IQR 301.75–643.25). On histopathologic examination, 50% showed mild portal fibrosis and mild diffuse bile ductular proliferation in 5 cases (62.5%). On the other hand, those diagnosed as obstructive cholestasis (179) by histopathologic examination included 154 cases confirmed to be BA, 3 cases of choledochal cyst, 10 cases of PFIC-3, 7 cases as Alagille syndrome (paucity), and 5 metabolic causes including alpha-1 antitrypsin deficiency. The non-BA cases misdiagnosed histologically as obstructive cholestasis did not experience any unnecessary surgical intervention.

Kasai procedure

At a mean age of 75.46 months, 142 BA group cases (87.7%) underwent Kasai surgery. An intraoperative cholangiogram was performed for all patients. The excised atretic segment was received and labelled, and the diameter of the bile ductule was measured using a DP50 camera (Olympus, Tokyo, Japan) equipped with an Olympus BX31 microscope. Only 28 operated cases (19.7%) developed hepatic encephalopathy. Those who did not have a Kasai procedure (20 cases) included 11 cases presented late with advanced fibrosis, as well as 9 cases where the parents refused to have surgery due to their belief that natural herbs would solve the problem.
Because the patient’s age is critical for the Kasai procedure [10], we divided all 162 clinically proven BA cases into two groups according to age (≤ 6 weeks and > 6 weeks, Supp Table 5). Histopathologic features of obstruction such as portal edema, advanced portal fibrosis, and bile ductular proliferation were more common in infants > 6 weeks of age (P < .001).

Concordance of liver biopsy with final diagnosis

When studying the histopathologic concordance with the clinical diagnosis of BA, a liver biopsy assessed using the strict histopathologic criteria (Table 1) did perform well, with a sensitivity of 95.1%, specificity of 91.6%, PPV of 86%, and NPV of 97.1%. Concordance between the histopathologic and the clinical diagnosis of BA was 0.846 (perfect agreement).

Univariate and multivariate analysis of features associated with BA

The histopathologic predictors of BA identified by univariate analysis (Table 3) included portal edema, moderate and advanced portal fibrosis, ductular proliferation (mild diffuse or moderate/marked), bile duct/ductular plugs, DPM-like pattern, and cholangiolitis in addition to the absence of EMH or giant cell transformation of hepatocytes. Only portal edema, ductular proliferation (mild diffuse or moderate/marked), bile duct/ductular plugs, and cholangiolitis are the histopathologic predictors of BA according to multivariate analysis (Table 3).
Table 3
Univariate and multivariate analysis of histopathologic features associated with biliary atresia
Parameter
Univariate analysis
Multivariate analysis
HR a(95% CIb)
P value*
HR a (95% CIb)
P value*
1. Portal tract edema
247.13 (75.37–810.32)
P < .001
87.423 (22.22–343.97)
P < .001
2. Ductular proliferation
 Mild diffuse
106 (24.47–459.09)
P < .001
91.82 (11.68–721.71)
P <. 001
 Moderate or marked
228.24 (53.35–976.20)
P < .001
177.20 (21.88–1435.34)
P < .001
3. Bile duct/ductular plugs
119.98 (37.29-386.01)
P < .001
26.599 (6.54-108.21)
P < .001
4. Ductal plate malformation
11.45 (5.2-25.22)
P < .001
0.679 (0.178-2.6)
P < .001
5. Portal fibrosis
    
 Moderate fibrosis
7.89 (4.83–12.89)
P < .001
1.37 (0.701–2.69)
P = .35
 Advanced fibrosis
23.55 (4.97–111.49)
P < .001
7.91 (0.687–90.98)
P = .10
6. Cholestasis
    
 Moderate
4.81 (2.74–8.55)
P < .001
1.01 (0.438–2.34)
P = .98
 Marked
19.5 (1.91–199.14)
P < .001
0.685 (0.043–10.86)
P = .79
7. Cholangiolitis
5.28 (3.29–8.6)
P < .001
3.24 (1.86–7.24)
P = 0.03
8. Giant-cell transformation
0.326 (0.212–0.500)
P < .001
0.711 (0.301–1.68)
P = .44
9. EMHc
0.310 (0.204–0.473)
P < .001
0.807 (0.345–1.88)
P = .62
Abbreviations: aHR hazard ratio, bCI confidence interval, cEMH extramedullary hematopoiesis
*P < .05 is significant

Design of the diagnostic score for BA

There is no single diagnostic procedure that appears to be clearly superior for diagnosis of BA, rather a few diagnostic tools are used collectively to reach an early and accurate diagnosis. BA can only be correctly diagnosed by correlating the clinico-radiological features with histological findings [13]. In this study, all patients underwent an abdominal ultrasound, which gave a detailed report about the gall bladder length, contractility, triangular cord sign, and extra and intrahepatic biliary radicles with a clear comment on any abnormality as if the gallbladder (non-contractile or rudimentary or non-visualized). When radiology was non-conclusive or negative and the liver biopsy showed a picture of obstructive cholestasis, hepatobiliary scans (HIDA showing no excretion of radiotracer) and intraoperative cholangiogram were done to reach a definite diagnosis.
Serum levels of GGT are not required, but their high elevation (10 times normal) supports the diagnosis. Patient age was taken into consideration when assessing both the liver biopsy pathologically and the level of GGT. The AUC of serum GGT levels in relation to age group was 0.812 in neonate ≤ 60 days, 0.868 in infants aged 61–90 days, and 0.940 in those aged 91–120 days (Supp Figure 2). The cutoff of GGT in patients with BA ≤ 60 days was 309.5 IU/L with 82.4% sensitivity and 72.7% specificity. The cutoff increased to 347.5 IU/L with increasing age (61–90 days) with 88.6% sensitivity and 80.6% specificity. Despite that the cutoff value of GGT decreased to 295 IU/L at age (91–120 days), its sensitivity and specificity increased to 93.3% and 83.9%, respectively.
When all histopathologic features of obstruction are diffusely present (> 50% of portal tracts), a total score of 2 is given regardless of patient age. When some of these features are present or when all features are detected focally (< 50% of portal tracts), then referral to patient age is essential for scoring (Table 4).
Table 4
The diagnostic scoring system for biliary atresia
Items
 
Points
Clay stool
Present and persistent
Absent
2
0
Radiology
Suggestive of biliary atresia
No abnormal features*
2
0
Liver biopsy
Portal edema, bile duct/ductular plugs, and moderate to marked bile ductular proliferation (Alla)
2
Some but not allb
 
• ≤ 6weeks
• >6 weeks (42 days)
None
2
1
0
GGTc
Elevated (10 times normal for age )
1
Normal
0
Total score
 
≥ 5 definite biliary atresia
4 probable
≤ 3 NOT biliary atresia
*No abnormal features after evaluating 2 different methods of assessment as ultrasound (US) and hepatobiliary scans
aAll, indicates that these features should be present combined in more than 50% of portal tracts
bSome, either not all features present or present focally (<50% of portal tracts)
cGGT gamma-glutamyl-transferase
We assigned points to each of the 4 aforementioned parameters (Table 4). This score was then validated across all cases in the study (BA and non-BA cases). We found a sensitivity of 100% and a specificity of 93.3% at a cutoff of 3, 100% sensitivity and 100% specificity at a cutoff of 4, 95.1% sensitivity and 100% specificity at a cutoff of 5, and 78.4% sensitivity and 100% specificity at a cutoff of 6 points.
Since patient’s age can affect the histopathologic features of BA, we investigated all the study cases aged less than 6 weeks to evaluate how the diagnostic score will perform. Only 3 cases out of 19 cases of Paucity/Allagille and 2 cases of PFIC-3 got a score of 3, while 8 (30.8%) out of 26 cases of BA got a score of 4. When the total score is equivocal for BA, proceeding with an intraoperative cholangiogram may be the most effective and quick strategy to avoid the drawbacks of a delayed BA diagnosis, such as a delayed Kasai surgery and the higher possibility of a liver transplant.

Discussion

A liver biopsy is advised for the purpose of diagnosing NC. Many cholestatic disorders are expressed differently over time. Additionally, liver biopsy can reveal disease-specific findings, such as the paucity of ducts in Alagille syndrome [2].
This study included a large number of liver biopsies in infants who presented with cholestasis. We investigated all histopathologic features in an attempt to clearly define those with obstructive versus non-obstructive cholestasis. Histopathologic characteristics closely related to BA (portal edema, bile ductular proliferation, and plugs) concurred with those made by Russo et al. [20, 21] and Zerbini et al. [25]. According to Ferry et al. [11], the primary characteristic of biopsies taken from BA patients is bile duct proliferation.
A small number of pathologists were involved in several published papers from single institutions on the reliability of liver biopsy for the diagnosis of BA [1, 10, 18]. In our study, the liver biopsy resulted in a concordance rate of 0.846 for the diagnosis of BA. Brough and Bernstein [3] found an accuracy of 93.7% for the pathologic diagnosis. Additionally, Ferry et al. [11] reported retrospectively that in 94% of 143 cases, the first liver biopsy accurately predicted the clinical diagnosis.
BA has been identified using GGT activity in serum. Serum GGT > 300 IU/L or a daily increase of 6 IU/L can be used to distinguish between BA and neonatal hepatitis. The accuracy of GGT measurement for the diagnosis of BA is increased by correlation with the reference range for GGT, which is dependent on age [5].
Many centers begin to rely on the serum level of matrix metalloproteinase-7 (MMP-7) for the diagnosis of BA. While the potential of MMP-7 to diagnose BA is clear, there is not much research performed on where exactly in the pathophysiology of BA, MMP-7 can be a factor. Sakaguchi et al. [22] and the review by Tang et al. [24] found that serum MMP-7 is a useful marker for the diagnosis of BA. However, Karbasian et al. [14] questioned the diagnostic value of MMP7 in differentiating BA from non-BA cases in the Middle Eastern population. They stated that MMP7 lacks enough specificity and lower diagnostic accuracy compared to GGT in diagnosing BA from other causes of NC. Our study is a retrospective one where serum MMP-7 was only introduced to our center by the year 2017. In addition, there is still debate about it together with the lack of clear cutoff values that distinguished infants with BA from those without [24].
Most of the scoring systems proposed for BA were based on histopathologic features to increase the accuracy of pathological evaluation of liver biopsy. Chen et al. [4] established a 21-point histological scoring system and found that a score of ≥ 8 had the best diagnostic utility to differentiate BA from other intrahepatic cholestasis histologically (sensitivity 94.7%, specificity 86.2%, accuracy 91.9%). Russo et al. [20] stated that the diagnostic accuracy of the needle biopsy was estimated to be 90.1%, whereas sensitivity and specificity for a diagnosis of BA are 88.4% and 92.7%, respectively. Zhao et al. [26] did not use the histopathologic feature in their scoring system and only relied on the use of glycochenodeoxycholic acid/chenodeoxycholic acid, clay stool, and GGT. A cutoff value of 15 from a total score of 41 identified BA with 90% sensitivity and 80% specificity in a validation cohort. Lee and Looi [16] used a detailed 15 points of 7 features assessed histopathologically only for the diagnosis of BA without including the clinical data. Their results showed that a score of ≥ 7 had the best diagnostic utility to differentiate BA from other intrahepatic cholestasis histologically (sensitivity 88%, specificity 94%, accuracy 92%). Our scoring system is similar to some extent to the scoring system for BA designed by El-Guindi et al. [9] who proposed a 12 points scoring system. A cutoff value of > 23.927 could discriminate BA from other causes of neonatal cholestasis with sensitivity of 100% and the accuracy was 98.83% in predicting BA. However, ours is simpler, easier to use in day-to-day practice, and included a larger study group (459 cases).
This study has several limitations. First, it is a single-center retrospective study. Second, this study did not address the prognostic value of histologic characteristics of a liver biopsy performed for NC. Third, this scoring system needs to be validated by other investigators.
In conclusion, we have shown detailed histopathologic features of BA with more depth to those presented earlier than 6 weeks of age and developed a simple scoring system for BA. However, it is impossible to make a diagnosis based solely on a biopsy but with correlation with clinical, radiologic, and laboratory information, the standard of care for these infants will take place.

Declarations

The authors confirm that the work complies with ethical standards.

Conflict of interest

The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Jetzt e.Med zum Sonderpreis bestellen!

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt bestellen und 100 € sparen!

Anhänge

Supplementary information

Literatur
1.
Zurück zum Zitat Alagille D, Gautier M, Habib E, Dommergues J (1969) Pre-and postoperative hepatic biopsy data in prolonged cholestasis in infants. Study of 128 cases Arch Francaises de Pediatr 26:283–296 Alagille D, Gautier M, Habib E, Dommergues J (1969) Pre-and postoperative hepatic biopsy data in prolonged cholestasis in infants. Study of 128 cases Arch Francaises de Pediatr 26:283–296
2.
Zurück zum Zitat Bellomo-Brandao MA, Escanhoela CA, Meirelles LR, Porta G, Hessel G (2009) Analysis of the histologic features in the differential diagnosis of intrahepatic neonatal cholestasis. World J Gastroenterol 15:478CrossRefPubMedPubMedCentral Bellomo-Brandao MA, Escanhoela CA, Meirelles LR, Porta G, Hessel G (2009) Analysis of the histologic features in the differential diagnosis of intrahepatic neonatal cholestasis. World J Gastroenterol 15:478CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Brough AJ, Bernstein J (1974) Conjugated hyperbilirubinemia in early infancy: a reassessment of liver biopsy. Human Pathol 5:507–516CrossRef Brough AJ, Bernstein J (1974) Conjugated hyperbilirubinemia in early infancy: a reassessment of liver biopsy. Human Pathol 5:507–516CrossRef
4.
Zurück zum Zitat Chen G, Xue P, Zheng S, Chen L, Ma Y (2015) A pathological scoring system in the diagnosis and judgment of prognosis of biliary atresia. J Pediatr Surg 50:2119–2123CrossRefPubMed Chen G, Xue P, Zheng S, Chen L, Ma Y (2015) A pathological scoring system in the diagnosis and judgment of prognosis of biliary atresia. J Pediatr Surg 50:2119–2123CrossRefPubMed
5.
Zurück zum Zitat Chen X, Dong R, Shen Z, Yan W, Zheng S (2016) Value of gamma-glutamyl transpeptidase for diagnosis of biliary atresia by correlation with age. J Pediatr Gastroenterol Nutr 63:370–373CrossRefPubMed Chen X, Dong R, Shen Z, Yan W, Zheng S (2016) Value of gamma-glutamyl transpeptidase for diagnosis of biliary atresia by correlation with age. J Pediatr Gastroenterol Nutr 63:370–373CrossRefPubMed
6.
Zurück zum Zitat Cho S-J, Kim GE (2019) A practical approach to the pathology of neonatal cholestatic liver disease. Semin Diagn Pathol:375–388 Cho S-J, Kim GE (2019) A practical approach to the pathology of neonatal cholestatic liver disease. Semin Diagn Pathol:375–388
7.
Zurück zum Zitat Cho S-J, Perito ER, Shafizadeh N, Kim GE (2021) Dialogs in the assessment of neonatal cholestatic liver disease. Human Pathol 112:102–115CrossRef Cho S-J, Perito ER, Shafizadeh N, Kim GE (2021) Dialogs in the assessment of neonatal cholestatic liver disease. Human Pathol 112:102–115CrossRef
8.
Zurück zum Zitat Dezsofi A, Baumann U, Dhawan A, Durmaz O, Fischler B, Hadzic N, Hierro L, Lacaille F, McLin VA, Nobili V (2015) Liver biopsy in children: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 60:408–420CrossRefPubMed Dezsofi A, Baumann U, Dhawan A, Durmaz O, Fischler B, Hadzic N, Hierro L, Lacaille F, McLin VA, Nobili V (2015) Liver biopsy in children: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 60:408–420CrossRefPubMed
9.
Zurück zum Zitat El-Guindi MA-S, Sira MM, Sira AM, Salem TA-H, El-Abd OL, Konsowa HA-S, El-Azab DS, Allam AA-H (2014) Design and validation of a diagnostic score for biliary atresia. J Hepatol 61:116–123CrossRefPubMed El-Guindi MA-S, Sira MM, Sira AM, Salem TA-H, El-Abd OL, Konsowa HA-S, El-Azab DS, Allam AA-H (2014) Design and validation of a diagnostic score for biliary atresia. J Hepatol 61:116–123CrossRefPubMed
10.
Zurück zum Zitat Fawaz R, Baumann U, Ekong U, Fischler B, Hadzic N, Mack CL, McLin VA, Molleston JP, Neimark E, Ng VLJJopg, nutrition (2017) Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 64:154–168CrossRefPubMed Fawaz R, Baumann U, Ekong U, Fischler B, Hadzic N, Mack CL, McLin VA, Molleston JP, Neimark E, Ng VLJJopg, nutrition (2017) Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 64:154–168CrossRefPubMed
11.
Zurück zum Zitat Ferry GD, Selby ML, Udall J, Finegold M, Nichols B (1985) Guide to early diagnosis of biliary obstruction in infancy: review of 143 cases. Clin Pediatr 24:305–311CrossRef Ferry GD, Selby ML, Udall J, Finegold M, Nichols B (1985) Guide to early diagnosis of biliary obstruction in infancy: review of 143 cases. Clin Pediatr 24:305–311CrossRef
12.
Zurück zum Zitat Götze T, Blessing H, Grillhösl C, Gerner P, Hoerning A (2015) Neonatal cholestasis–differential diagnoses, current diagnostic procedures and treatment. Front Pediatr 3:43PubMedPubMedCentral Götze T, Blessing H, Grillhösl C, Gerner P, Hoerning A (2015) Neonatal cholestasis–differential diagnoses, current diagnostic procedures and treatment. Front Pediatr 3:43PubMedPubMedCentral
14.
Zurück zum Zitat Karbasian F, Mashhadiagha A, Anbardar MH, Ataollahi M, Dehghani SM, Honar N, Haghighat M, Imanieh MH, Sayadi M, Shahramian I, Aghsam A, Hosseini A, Mahadavi Mortazavi SM, Darban B, Avazpour A, Mirrahimi B, Ruzbahani AK, Tadayon A (2023) Questioning Diagnostic Value of Serum Matrix Metalloproteinase 7 for Biliary Atresia. J Clin Exp Hepatol. 13(2):265–272CrossRefPubMed Karbasian F, Mashhadiagha A, Anbardar MH, Ataollahi M, Dehghani SM, Honar N, Haghighat M, Imanieh MH, Sayadi M, Shahramian I, Aghsam A, Hosseini A, Mahadavi Mortazavi SM, Darban B, Avazpour A, Mirrahimi B, Ruzbahani AK, Tadayon A (2023) Questioning Diagnostic Value of Serum Matrix Metalloproteinase 7 for Biliary Atresia. J Clin Exp Hepatol. 13(2):265–272CrossRefPubMed
16.
Zurück zum Zitat Lee WS, Looi LM (2009) Usefulness of a scoring system in the interpretation of histology in neonatal cholestasis. World J Gastroenterol WJG 15:5326CrossRefPubMed Lee WS, Looi LM (2009) Usefulness of a scoring system in the interpretation of histology in neonatal cholestasis. World J Gastroenterol WJG 15:5326CrossRefPubMed
17.
Zurück zum Zitat López Panqueva RdP (2014) Approaches to pathological diagnosis of cholestatic diseases. Revista colombiana de Gastroenterología 29:189–199 López Panqueva RdP (2014) Approaches to pathological diagnosis of cholestatic diseases. Revista colombiana de Gastroenterología 29:189–199
18.
Zurück zum Zitat Nezelof C (1972) Histological findings in neonatal hepatitis. Am J Dis Child 123:299PubMed Nezelof C (1972) Histological findings in neonatal hepatitis. Am J Dis Child 123:299PubMed
19.
Zurück zum Zitat Nicastro E, Di Giorgio A, Marchetti D, Barboni C, Cereda A, Iascone M, D` Antiga L (2019) Diagnostic yield of an algorithm for neonatal and infantile cholestasis integrating next-generation sequencing. J Pediatr 211:54–62. e54CrossRefPubMed Nicastro E, Di Giorgio A, Marchetti D, Barboni C, Cereda A, Iascone M, D` Antiga L (2019) Diagnostic yield of an algorithm for neonatal and infantile cholestasis integrating next-generation sequencing. J Pediatr 211:54–62. e54CrossRefPubMed
20.
Zurück zum Zitat Russo P, Magee JC, Anders RA, Bove KE, Chung C, Cummings OW, Finegold MJ, Finn LS, Kim GE, Lovell MA (2016) Key histopathological features of liver biopsies that distinguish biliary atresia from other causes of infantile cholestasis and their correlation with outcome: a multicenter study. Am J Surg Pathol 40:1601–1615CrossRefPubMedPubMedCentral Russo P, Magee JC, Anders RA, Bove KE, Chung C, Cummings OW, Finegold MJ, Finn LS, Kim GE, Lovell MA (2016) Key histopathological features of liver biopsies that distinguish biliary atresia from other causes of infantile cholestasis and their correlation with outcome: a multicenter study. Am J Surg Pathol 40:1601–1615CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Russo P, Magee JC, Boitnott J, Bove KE, Raghunathan T, Finegold M, Haas J, Jaffe R, Kim GE, Magid M (2011) Design and validation of the biliary atresia research consortium histologic assessment system for cholestasis in infancy. Clin Gastroenterol Hepatol 9:357–362CrossRefPubMedPubMedCentral Russo P, Magee JC, Boitnott J, Bove KE, Raghunathan T, Finegold M, Haas J, Jaffe R, Kim GE, Magid M (2011) Design and validation of the biliary atresia research consortium histologic assessment system for cholestasis in infancy. Clin Gastroenterol Hepatol 9:357–362CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Sakaguchi H, Ki K, Yasuda R, Sasaki H, Yoshimaru K, Tainaka T, Fukahori S, Sanada Y, Iwama I, Shoji H (2022) Serum matrix metalloproteinase-7 in biliary atresia: a Japanese multicenter study. Hepatol Res 52:479–487CrossRefPubMed Sakaguchi H, Ki K, Yasuda R, Sasaki H, Yoshimaru K, Tainaka T, Fukahori S, Sanada Y, Iwama I, Shoji H (2022) Serum matrix metalloproteinase-7 in biliary atresia: a Japanese multicenter study. Hepatol Res 52:479–487CrossRefPubMed
23.
Zurück zum Zitat Shneider BL, Brown MB, Haber B, Whitington PF, Schwarz K, Squires R, Bezerra J, Shepherd R, Rosenthal P, Hoofnagle JH (2006) A multicenter study of the outcome of biliary atresia in the United States, 1997 to 2000. J Pediatr 148:467–474. e461CrossRefPubMed Shneider BL, Brown MB, Haber B, Whitington PF, Schwarz K, Squires R, Bezerra J, Shepherd R, Rosenthal P, Hoofnagle JH (2006) A multicenter study of the outcome of biliary atresia in the United States, 1997 to 2000. J Pediatr 148:467–474. e461CrossRefPubMed
25.
Zurück zum Zitat Zerbini M, Gallucci S, Maezono R, Ueno C, Porta G, Maksoud J, Gayotto L (1997) Liver biopsy in neonatal cholestasis: a review on statistical grounds Modern Pathology: an Official Journal of the United States and Canadian Academy of Pathology. INC 10:793–799 Zerbini M, Gallucci S, Maezono R, Ueno C, Porta G, Maksoud J, Gayotto L (1997) Liver biopsy in neonatal cholestasis: a review on statistical grounds Modern Pathology: an Official Journal of the United States and Canadian Academy of Pathology. INC 10:793–799
Metadaten
Titel
Pathologic approach to Neonatal cholestasis with a simple scoring system for biliary atresia
verfasst von
Khadiga M. Ali
Khaled R. Zalata
Tarik Barakat
Sherine M. Elzeiny
Publikationsdatum
27.11.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 1/2024
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-023-03704-5

Weitere Artikel der Ausgabe 1/2024

Virchows Archiv 1/2024 Zur Ausgabe

Neu im Fachgebiet Pathologie

Assistierter Suizid durch Infusion von Thiopental

Thiopental Originalie

Als Folge des Urteils des Bundesverfassungsgerichts zur Sterbehilfe im Jahr 2020 wurde in den Jahren 2021–2023 eine Reihe (n = 23) von assistierten Suiziden im Landesinstitut für gerichtliche und soziale Medizin Berlin mit jeweils identischen …

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …